Manchester, UK, December 17 2012 – Conformetrix Ltd, a leader in optimising
drug discovery and design, is pleased to announce progress in its lead proprietary
programme, focused on selective inhibition of the orexin-1 receptor (OX1R). The
company has generated a series of potent antagonists, which it plans to evaluate
and progress to drug leads. Orexin is a neurotransmitter believed to play a role in a
broad range of behavioural conditions, from sleep disorders to addiction.
While there are two receptors for orexin, OXR1 and OXR2, emerging prec
linical data supports the use of selective OXR1 antagonists in the treatment of disorders
specifically associated with panic, anxiety and compulsive behaviours. Using its
proprietary NMR-based technology for structural determination, Conformetrix has
built a universal 3D (or “pharmacophore”) map of existing OXR1 and OXR2 binders.
The company was able to use this to design low nanomolar inhibitors with
substantial selectivity for OXR1 over OXR2 in just a few months.
Dr Clive Dix, Chairman of Conformetrix, said, ‘Our ability to rapidly design these
antagonists highlights the disruptive nature of Conformetrix’s technology and its
potential to significantly increase the efficiency of the drug discovery process. Orexin
represents the first of several therapeutically important targets to which Conformetrix
is applying its technology, about which we intend to make similar announcements
over the course of 2013.'
For further information please contact:
Sam Williams, CEO +44 (0)7881 588947
Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185
About Conformetrix Ltd
Conformetrix is a Manchester, UK-based company focused on optimising drug discovery
and design. It was founded in 2008 as a spin-out from the University of Manchester. The
company uses its NMR-based technology to solve the dynamic 3D structures of a broad
range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates.
Since Conformetrix's NMR technology shows what shapes molecules adopt when they are active, it provides high-quality templates for drug discovery and design, and valuable
information for drug candidate optimisation. In addition, the data is generated faster and
more cheaply than by standard techniques such as X-ray crystallography. Conformetrix has
solved structures for several large pharmaceutical companies, as well as developing
proprietary drug programmes, and recently signed a collaboration with AstraZeneca. It has
been funded since inception by specialist life science investor Aquarius Equity Partners. For
more information, please go to www.conformetrix.com.
About Conformetrix's technology
Conformetrix’s NMR technology determines accurate three-dimensional structures - or
conformations - of drug molecules in their bioactive states. This is achieved without the need
for traditional structural information regarding the protein target of each drug, thereby
providing researchers with valuable information on how development-stage compounds are
likely to interact with their targets. This new information should improve the efficiency and
quality of the lead identification, lead optimisation and candidate selection stages of drug